Advertisements



We are Sorry, This Page doesn't Exist


Cara Therapeutics Rallies On Positive Clinical Readout For Pruritis Drug

Small-cap biotech Cara Therapeutics Inc (NASDAQ: CARA) is trading to its highest level since early April after it released the results of a Phase 3 trial for its lead candidate Korsuva. read more.....»»

Category: blogSource: benzingaMay 29th, 2019

Vistagen Shares Fall Under $1 After Depression Drug Flunks Midstage Trial

Vistagen Therapeutics Inc (NASDAQ: VTGN) shares were nearly cut in half Thursday following adverse results from a Phase 2 study evaluating its treatment-resistant depression (TRD) drug candidate. read more.....»»

Category: blogSource: benzingaMay 2nd, 2019

Nabriva Therapeutics unveils positive results in bacterial pneumonia drug trial

Nabriva Therapeutics PLC on Monday reported positive results in a a late-stage trial of a treatment for bacterial pneumonia, saying the phase 3 trial of Lefamulin Evaluation Against Pneumonia (LE.....»»

Category: topSource: marketwatchMay 21st, 2018

Ovid Therapeutics shares fall 28% as investors question new drug data (OVID)

Markets Insider New York-based biotech company Ovid Therapeutics announced on Monday positive phase 2 trial results for its treatment for a rare disease called Angelman Syndrom.....»»

Category: topSource: businessinsiderAug 6th, 2018

Viking Therapeutics stock rose 87% on results for its liver disease drug — and the company has more in store this fall

The company’s midstage clinical trial had positive results, and the condition in question affects an estimated 100 million people in the U.S......»»

Category: topSource: marketwatchSep 18th, 2018

Viking Therapeutics stock jumps 4.8% premarket on news of positive trial results

Viking Therapeutics Inc. shares surged x% in premarket trade Monday, after the company reported positive results in a mid-stage trial of a treatment for broken hips. The company said its Phase 2 trial of VK5.....»»

Category: topSource: marketwatchOct 1st, 2018

Mirati Therapeutics stock drops 30% premarket after cancer trial results

Mirati Therapeutics Inc. shares dropped 30% in Monday premarket trade after the company presented results from a phase 2 trial in which its cancer drug sitravatinib was combined with Bristol-Myers Squibb Co.'s cancer drug Opdivo . The trial enrolled p.....»»

Category: topSource: marketwatchOct 22nd, 2018

Small-Cap Cancer Drug Developer Agenus" Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. Latest Ratings for A.....»»

Category: blogSource: benzingaApr 12th, 2024

Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program

Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data. read more.....»»

Category: blogSource: benzingaApr 11th, 2024

Magenta Therapeutics announces results from Phase 2 trial of MGTA-145

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 12th, 2021

Cara Therapeutics announces results from KARE phase 2 trial of KORSUVA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 29th, 2021

TG Therapeutics reports publication of final results from Phase 3 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 23rd, 2021

Enlivex Therapeutics reports topline results from Phase II trial of Allocetra

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 3rd, 2021

Obalon Therapeutics stock soars to lead all gainers on massive volume after merger with ReShape

Shares of Obalon Therapeutics Inc. blasted five-fold higher on massive volume in midday trading Wednesday, after the weight loss technologies company announced an agreement to merge with weight loss solutions company ReShape L.....»»

Category: topSource: marketwatchJan 20th, 2021

Axsome Therapeutics announces results from Phase 3 MOVEMENT trial of AXS-07

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 31st, 2020

Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights

Phase 1/2 Trial of PR001 for Parkinson's Disease with GBA1 Mutations Ongoing; Study.....»»

Category: earningsSource: benzingaMay 14th, 2020

Evelo Biosciences Reports First Quarter Financial Results and Business Highlights

–Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during.....»»

Category: earningsSource: benzingaMay 11th, 2020

Ovid Therapeutics announces results from Phase 2 ROCKET trial of OV101

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 7th, 2020

Akebia"s shares jump on late-stage clinical trial results for kidney disease drug

Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on.....»»

Category: topSource: marketwatchMay 5th, 2020

Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

Dosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson's Disease with GBA1 Mutations Preparations Underway to Initiate PROVIDE Phase 1/2 Trial of PR001 .....»»

Category: earningsSource: benzingaMar 26th, 2020